Gary Clark: Unfiltered

Insightful analysis on the financial currents, corporate maneuvers, and innovations defining our era.

GC
Editor
Gary Clark
326 Total Articles
14 This Week

About This Column

Gary Clark is a commentator and strategist exploring the intersection of finance and industrial transformation. Transitioning from his deep dive into corporate maneuvers, Gary now delivers daily dispatches on the broad forces defining the 2026 economic landscape - from the evolution of global supply chain finance to the impact of AI on asset allocation. With a reputation for providing "the story behind the numbers," he offers a unique lens on what drives market performance in a complex world. His writing is essential for anyone seeking to understand the "why" of today’s market to predict the "what" of tomorrow.

Recent Articles

Gary Clark: Unfiltered about 2 months ago

Long-Term Data Bolsters Rigel's REZLIDHIA in AML Battle

Five-year results from a Phase 2 trial show durable responses with REZLIDHIA in relapsed/refractory AML patients, even those previously treated with venetoclax. The data signals potential for expanded use and market growth.

Read full article
Long-Term Data Bolsters Rigel's REZLIDHIA in AML Battle
Gary Clark: Unfiltered about 2 months ago

Angiex Secures $31M to Advance Novel Nuclear-Delivered Cancer Therapy

Biotech firm Angiex Inc. has raised $31 million to support Phase 1 trials of AGX101, a first-in-class antibody-drug conjugate designed to deliver cancer-killing drugs directly into tumor cell nuclei, offering a potentially more effective and targeted treatment.

Read full article
Angiex Secures $31M to Advance Novel Nuclear-Delivered Cancer Therapy
Gary Clark: Unfiltered about 2 months ago

Silo Pharma's Novel PTSD Approach & Risky Crypto Bet: A Deep Dive

Silo Pharma partners with Allucent to advance a novel PTSD treatment while doubling down on a controversial cryptocurrency treasury strategy. Can this biopharmaceutical firm navigate both innovative science and volatile digital assets?

Read full article
Silo Pharma's Novel PTSD Approach & Risky Crypto Bet: A Deep Dive
Gary Clark: Unfiltered about 2 months ago

Acumen’s Alzheimer’s Candidate Enters Key Trial Phase, Targeting Toxic Brain Proteins

Biotech firm Acumen Pharmaceuticals begins a long-term extension of its Phase 2 Alzheimer’s trial, focusing on a novel approach to combatting the disease by targeting soluble amyloid beta oligomers. Is this a turning point for Alzheimer's treatment?

Read full article
Acumen’s Alzheimer’s Candidate Enters Key Trial Phase, Targeting Toxic Brain Proteins
Gary Clark: Unfiltered about 2 months ago

Arcutis Poised to Fill Unmet Need with Pediatric Psoriasis Treatment

The FDA has accepted a supplemental application for Arcutis Biotherapeutics’ ZORYVE cream, potentially offering the first-ever topical treatment for plaque psoriasis in children as young as 2 years old, addressing a significant gap in care.

Read full article
Arcutis Poised to Fill Unmet Need with Pediatric Psoriasis Treatment
Gary Clark: Unfiltered about 2 months ago

TGS Deepens Brazil Bet: Pelotas Basin Emerges as Key Oil Frontier

TGS launches a major 3D seismic survey in Brazil's Pelotas Basin, signaling growing interest in this underexplored region with significant oil potential. Advanced tech de-risks future exploration.

Read full article
TGS Deepens Brazil Bet: Pelotas Basin Emerges as Key Oil Frontier
UCID: 7